コンテンツへスキップ
About Us
Message from CEO
Our Mission
Company Profile
Management Team
History
Clinical Development
Ongoing Clinical Studies
MN-166 (Ibudilast)
About MN-166 (Ibudilast)
ALS
Oncology / Glioblastoma
DCM
CIPN
ARDS / Lung Injury
MN-001 (Tipelukast)
About MN-001（Tipelukast)
NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
Investor Relations
Press Release
Event
Media Archive
Annual Report
SEC filing
Stock Quote -TSE
Stock Quote -Nasdaq
Historical Price Lookup
Investment Calculator
Analyst Coverage
Corporate Governance
Information Request
Presentation
Corporate Presentation & Resarch Reports
MN-166 Presentation
Progressive Multiple Sclerosis (Progressive MS)
Amyotrophic Lateral Sclerosis (ALS)
Oncology / Glioblastoma
Substance Dependence and Addiction
MN-166 (ibudilast) News Articles
MN-166 (ibudilast) Publications
MN-001 Presentation
Contact Us
Contact Us
Japanese site
About Us
Message from CEO
Our Mission
Company Profile
Management Team
History
Clinical Development
Ongoing Clinical Trial
MN-166 (Ibudilast)
About MN-166 (Ibudilast)
ALS
Oncology / Glioblastoma
DCM
CIPN
ARDS / Lung Injury
MN-001 ( tipelukast)
About MN-001（Tipelukast)
NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
Investor Relations
News
Events
Presentations
Stock Quote & Chart
TSE Stock Quote
Analyst Coverage
Equity Research
SEC Filings
Annual Reports
Documents & Charters
Email Alerts
Presentation
Corporate Presentation and Equity Research Analyst Reports
MN-166 Presentation
Progressive Multiple Sclerosis (Progressive MS)
Amyotrophic Lateral Sclerosis (ALS)
Oncology / Glioblastoma
Substance Dependence and Addiction
MN-166 (ibudilast) News Articles
MN-166 (ibudilast) Publications
MN-001 Presentation
Contact Us
平成19年12月期決算発表および決算説明会のお知らせ
2008.02.07
2017.11.27
多発性硬化症を適応とするMN-166のフェーズ2臨床試験の追加解析結果のお知らせ
当社が2007年12月31日時点で保有する現金及び現金等価物並びに売却可能短期有価証券について
メニュー
About Us
Message from CEO
Our Mission
Company Profile
Management Team
History
Clinical Development
Ongoing Clinical Trial
MN-166 (Ibudilast)
About MN-166 (Ibudilast)
ALS
Oncology / Glioblastoma
DCM
CIPN
ARDS / Lung Injury
MN-001 ( tipelukast)
About MN-001（Tipelukast)
NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
Investor Relations
News
Events
Presentations
Stock Quote & Chart
TSE Stock Quote
Analyst Coverage
Equity Research
SEC Filings
Annual Reports
Documents & Charters
Email Alerts
Presentation
Corporate Presentation and Equity Research Analyst Reports
MN-166 Presentation
Progressive Multiple Sclerosis (Progressive MS)
Amyotrophic Lateral Sclerosis (ALS)
Oncology / Glioblastoma
Substance Dependence and Addiction
MN-166 (ibudilast) News Articles
MN-166 (ibudilast) Publications
MN-001 Presentation
Contact Us
検索
